Linked Life Data

15361886

Source:http://linkedlifedata.com/resource/pubmed/id/15361886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2004-11-23
pubmed:abstractText
Generation of angiotensin II (Ang II) contributes to the pathogenesis of cardiovascular diseases. Owing to the existence of high levels of Ang II within the kidney, blockade of the intrarenal Ang II levels may be important since long term outcome seems not only to be related to blood pressure per se. This was a prospective, randomized, double-blind, placebo-controlled study, with crossover design. We examined in 13 patients with mild to moderate hypertension the specific systemic and renal blocking properties of two different Ang II receptor blockers during a wide range of Ang II concentrations, 24 h post dose. The effects were evaluated after 4 weeks treatment with candesartan cilexetil (16 mg OD), losartan (50 mg OD) and placebo using clearance techniques. Candesartan reduced the 24 h blood pressure better than losartan (138(*)/87+/-12/8 vs 145/89+/-12/7 mmHg, (*)P<0.05 vs losartan) and placebo. Despite the lower blood pressure, candesartan attenuated the Ang II-induced response on ERPF and RVR markedly better than losartan or placebo. The GFR decreased, as expected, with placebo, but remained stable with candesartan. The present study demonstrates that in hypertensive patients candesartan and to a lesser degree losartan are effective in blocking the systemic and renal effects of Ang II during a wide range of Ang II infusion rates. Interestingly, 24 h post dose, candesartan effectively diminished the change in ERPF as well as GFR. This sustained renal effect of candesartan may be of importance, especially in pathophysiological circumstances in which (high renal levels of) Ang II contributes to cardiovascular damage.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0950-9240
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
857-63
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:15361886-Adult, pubmed-meshheading:15361886-Aged, pubmed-meshheading:15361886-Angiotensin II, pubmed-meshheading:15361886-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:15361886-Benzimidazoles, pubmed-meshheading:15361886-Biphenyl Compounds, pubmed-meshheading:15361886-Child, pubmed-meshheading:15361886-Cross-Over Studies, pubmed-meshheading:15361886-Dose-Response Relationship, Drug, pubmed-meshheading:15361886-Double-Blind Method, pubmed-meshheading:15361886-Female, pubmed-meshheading:15361886-Hemodynamics, pubmed-meshheading:15361886-Humans, pubmed-meshheading:15361886-Hypertension, pubmed-meshheading:15361886-Kidney, pubmed-meshheading:15361886-Losartan, pubmed-meshheading:15361886-Middle Aged, pubmed-meshheading:15361886-Renal Circulation, pubmed-meshheading:15361886-Renin, pubmed-meshheading:15361886-Tetrazoles
pubmed:year
2004
pubmed:articleTitle
Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
pubmed:affiliation
Department of Nephrology, University Medical Center, Utrecht, The Netherlands. jmrwillemsen@planet.nl
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't